ReviewIn vitro–in vivo correlation in p-glycoprotein mediated transport in intestinal absorption
Introduction
Drug development is a very laborious and expensive process. One of the major reasons for failures occurring during the clinical phases of drug development is the inadequate pharmacokinetic properties of the drug candidate. Therefore, it would be advantageous if the pharmacokinetic properties of drug candidates could be predicted beforehand. One major obstacle in making such predictions is the inability to appropriately scale the preclinical in vitro data to the in vivo situation.
The P-glycoprotein (P-gp) is an efflux protein which extrudes a wide variety of chemically different xenobiotics from cells (Mizuno et al., 2003). P-gp is widely expressed in many pharmacokinetic barriers in the body such as intestine, kidney, liver and blood–brain barrier (BBB). Therefore, it may affect significantly the pharmacokinetics of its substrate molecules. For this reason, drug candidates are screened for their interaction with P-gp already during the early stages of drug development (Balimane et al., 2006). There are several in vitro methods used to identify P-gp substrates, though the cell based bidirectional permeability assay is the most popular (Polli et al., 2001). However, the extent to which the in vitro data can predict the impact of P-gp in vivo, remains unclear.
When drugs are delivered via the peroral route, P-gp may limit the intestinal absorption of the therapeutic agent. The purpose of the present review was to examine the in vitro and in vivo data of P-gp on intestinal drug absorption, the in vitro and in vivo correlation (IVIVC) in the literature, and the factors to be taken into account in order to obtain a reliable IVIVC. The in vivo studies selected for this aim were done in P-gp-deficient mouse model: mdr1a(−/−) and mdr1a/1b(−/−) knockout mice and mdr1a(−/−) CF-1 mutant mice.
Section snippets
P-gp structure and mechanism of action
P-gp belongs to the superfamily of ATP-binding cassette transporters (ABC transporters). Humans possess two known P-gp genes, MDR1 (ABCB1) and MDR3 (ABCB4). However, only the MDR1 gene encodes for the multidrug-resistance-related P-gp efflux pump (REFSEQ mRNA: NM_00927.3). In mice, P-gp is encoded by mdr1a (abcb1a) and mdr1b (abcb1b) and mdr2 (abcb4) and the genes that confer the multidrug-resistance phenotype are mdr1a and mdr1b. There is 82% homology of human MDR1 and mouse mdr1a with the
P-gp expression and physiological function
P-gp is over-expressed in many tumor cell lines. In fact it was initially identified in these cell lines (Juliano and Ling, 1976), but it is constitutively expressed also in nearly all barrier tissues of the body (intestine, kidney, liver and BBB).
Human MDR1 P-gp is prominent in the brush border of renal proximal tubules, in the biliary membrane of hepatocytes, in the apical membrane of the epithelial cells in the intestine, in the apical membrane of the capillary endothelial cells of brain and
Oral absorption
The most convenient route of administration of drugs is the peroral route because of the high level of patient safety and acceptance, and relatively low production cost. On the other hand, an oral drug will be therapeutically efficient only if it is absorbed from the gastrointestinal tract and can gain access to the systemic circulation in sufficient quantities. The bioavailability of a drug is defined as the fraction of the dose that appears intact in the systemic circulation. Major efforts
Conclusions
The present review shows the fact that only a few in vivo studies in P-gp-deficient mouse model have been carried out to determine the impact of P-gp on the extent of drug absorption. Moreover, there is a lack of consensus on the protocol of the experiments and the standard in vivo parameter to describe the P-gp function in absorption quantitatively. The ratio F or AQin vivo could serve as such in vivo parameters. However, the possible effects of first pass metabolism and exsorptional
Perspective
In the present review, the lack of a robust IVIVC of P-gp effect in intestinal drug absorption became evident. Better in vivo pharmacokinetic data are required and more specific in vitro parameters need to be calculated in order to determine a potential significant IVIVC. A significant IVIVC would demonstrate the capacity of the in vitro parameter used to predict the effect of intestinal P-gp in vivo. The approaches for IVIVC discussed in the present review are based on in vitro and in vivo
Acknowledgements
This work was financially supported by the Finnish Funding Agency for Technology and Innovation (TEKES).
The authors are associated with Biocenter Kuopio.
References (82)
- et al.
Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro
Pharm. Res.
(2003) - et al.
Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein
Pharm. Res.
(2001) - et al.
The power of the pump: mechanisms of action of P-glycoprotein (ABCB1)
Eur. J. Pharm. Sci.
(2006) - et al.
Caco-2 monolayers in experimental and theoretical predictions of drug transport
Adv. Drug Deliv. Rev.
(2001) - et al.
Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption
J. Pharm. Sci.
(2008) - et al.
Current industrial practices of assessing permeability and P-glycoprotein interaction
AAPS J.
(2006) - et al.
The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671
Eur. J. Pharm. Sci.
(2000) - et al.
Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine
Mol. Pharm.
(2007) - et al.
What have we learnt thus far from mice with disrupted P-glycoprotein genes?
Eur. J. Cancer
(1996) - et al.
Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of glycyrrhiza glabra
Drug Metab. Dispos.
(2007)
The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability
Eur. J. Pharm. Sci.
Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development
Curr. Drug Metab.
Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice
Pharm. Res.
Predicting P-glycoprotein effects on oral absorption: correlation of transport in caco-2 with drug pharmacokinetics in wild-type and mdr1a(−/−) mice in vivo
Pharm. Res.
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites
Proc. Natl. Acad. Sci. U.S.A.
The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues
Mol. Cell. Biol.
Tissue distribution, gender-divergent expression, ontogeny and chemical induction of multidrug resistance transporter genes (mdr1a, mdr1b, mdr2) in mice
Drug Metab. Dispos.
A good practice guide to the administration of substances and removal of blood, including routes and volumes
J. Appl. Toxicol.
P-glycoprotein-mediated intestinal and biliary digoxin transport in humans
Clin. Pharmacol. Ther.
Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and pgp (ABCB1)
Inflamm. Bowel Dis.
Biochemistry of multidrug resistance mediated by the multidrug transporter
Ann. Rev. Biochem.
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
J. Clin. Invest.
Comparison of drug transporter gene expression and functionality in caco-2 cells from 10 different laboratories
Eur. J. Pharm. Sci.
Protein concentration and pH affect the apparent P-glycoprotein-ATPase activation kinetics
Int. J. Pharm.
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Proc. Natl. Acad. Sci. U.S.A.
Determination of drug permeability and prediction of drug absorption in caco-2 monolayers
Nat. Protoc.
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir
Mol. Pharmacol.
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
J. Natl. Cancer Inst.
Role of blood–brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug
Br. J. Pharmacol.
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Biochim. Biophys. Acta
Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition
Pharm. Res.
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
Cancer Chemother. Pharmacol.
Kinetic analyses for species differences in P-glycoprotein-mediated drug transport
J. Pharm. Sci.
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
Pharm. Res.
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
J. Clin. Invest.
Decrease in intracellular concentration causes the shift in km value of efflux pump substrates
Drug Metab. Dispos.
Efflux transport systems for drugs at the blood–brain barrier and blood-cerebrospinal fluid barrier (part 2)
Drug Discov. Today
Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein
Drug Metab. Dispos.
P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin
Antimicrob. Agents Chemother.
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics
Clin. Cancer Res.
P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity
Toxicol. Appl. Pharmacol.
Cited by (43)
Progress and prospects of polysaccharide-based nanocarriers for oral delivery of proteins/peptides
2023, Carbohydrate PolymersValue of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban
2020, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :Caco-2 cells can be obtained either from the American Type Culture Collection (ATCC) or from the European Collection of Authenticated Cell Cultures (ECACC), and expression of the mRNA of proteins such as ABC and SLC transporters differs depending on source selected [15]. An in vitro-in vivo correlation (IVIVC) has been established for absorption studies using Caco-2 and MDCK cells, particularly for passive drug absorption, but there is no well-established IVIVC for predicting in vivo transporter-mediated DDIs from the results obtained in in vitro models [16–18]. Further investigative analyses concerning the experimental protocols used in in vitro assays are therefore needed to establish better IVIVCs for transporter-mediated DDIs.
Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4
2014, Bioorganic and Medicinal Chemistry LettersPhysicochemical characterization and in vitro permeation of an indirubin derivative
2013, European Journal of Pharmaceutical SciencesCitation Excerpt :The “thermodynamic solubility” is the solubility of both ionized and unionized species of the molecule in an equilibrium solution and at a specific pH (Box and Comer, 2008; Guo and Shen, 2004). A further hurdle for successful drug development may be involvement of membrane efflux transporters, especially P-glycoprotein (P-gp) efflux transporters, which are located on the apical side of intestinal cells, and limit the bioavailability of their substrates (del Amo et al., 2009). In this study, we determined the pKa, log D/log P, and solubility of E804 in aqueous and organic solvents.
Suitability of isolated rat jejunum model for demonstration of complete absorption in humans for bcs-based biowaiver request
2012, Journal of Pharmaceutical SciencesCitation Excerpt :Although there are no published data available with regard to glimepiride, its close structural analogue glibenclamide is a substrate for several transporters, including P-gp.92 It is uncertain how well in vitro studies actually predict in vivo efflux impact,93 but it is possible that the interplay of transporters might have a possible impact on glimepiride misclassification. With regard to BCS-based biowaiver approach, this would not represent any harm to patients because glimepiride BCS-based biowaiver based on isolated rat jejunum data would be probably rejected by regulatory authorities due to low-permeability classification, unless human data would prevail.
Determination of Rhodamine 123 in rat plasma utilizing liquid chromatography-tandem mass spectrometry
2011, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :Rhodamine 123 (R123) (2-(6-amino-3-imino-3H-xanthen-9-yl)benzoic acid methyl ester, C21H16N2O3·HCl, molecular weight of 344.4) has been widely used as substrate to evaluate the functional transport activity of P-glycoprotein (P-gp) in vivo [1–5,17].